The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Open accessAbstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers, including malignancies once considered untreatable. These agents, however, are associated with inflammation and tissue damage in multiple organs. Myocarditis has emerged as a serious ICI-associated toxicity, because, while seemingly infrequent, it is often fulminant and lethal. The underlying basis of ICI-associated myocarditis is not completely understood. While the importance of T cells is clear, the inciting antigens, why they are recognized, and the mechanisms leading to cardiac cell injury remain poorly characterized. These issues underscore the need for basic and clinical studies to define pathogenesis, identify predictive biomarkers, improve diagnostic strategies, and develop effective treatments. An improved understanding of ICI-associated myocarditis will provide insights into the equilibrium between the immune and cardiovascular systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This discovery suggests a potential involvement of autoreactive T cells targeting α -MyHC in the initiation and progression of other forms of myocarditis.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent cases of ICI myocarditis have expanded our insights into the role of α -MyHC-specific T cells in myocarditis development. 41-46”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ICI myocarditis emerges as an infrequent but potentially fatal condition associated with ICI therapies, especially when used in combination”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“PD-1 and PD-L1 blockers mediated similar responses in patients with advanced and otherwise untreatable melanoma, non–small cell lung carcinoma, and urothelial tumors (77, 78).”
BackgroundCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citation
Cited by
Sorted by citations
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 736
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 389
Self-citationT cells specific for α-myosin drive immunotherapy-related myocarditis
Axelrod, M. L., Meijers, W. C., Screever, E. M., Qin, J., Carroll, M. G., Sun, X., Tannous, E., Zhang, Y., Sugiura, A., Taylor, B. C., et al. (2022) · Nature · doi:10.1038/s41586-022-05432-3 · Cited by 367
Self-citationDeep insight into cytokine storm: from pathogenesis to treatment
Nie, J., Zhou, L., Tian, W., Liu, X., Yang, L., Yang, X., Zhang, Y., Wei, S., Wang, D. W., & Wei, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02178-y · Cited by 251
Emerging concepts in PD-1 checkpoint biology
Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H., & Freeman, G. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101480 · Cited by 203
Self-citationLehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178
Self-citationWon, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137
Inflammation in cancer: therapeutic opportunities from new insights
Xie, Y., Liu, F., Wu, Y., Zhu, Y., Jiang, Y., Wu, Q., Dong, Z., & Liu, K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02243-8 · Cited by 148
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 135
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Karlstaedt, A., Moslehi, J. J., & de Boer, R. A. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00698-6 · Cited by 130
Self-citationHarnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Self-citationJCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis
Nagai, T., Inomata, T., Kohno, T., Sato, T., Tada, A., Kubo, T., Nakamura, K., Oyama‐Manabe, N., Ikeda, Y., Fujino, T., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-22-0696 · Cited by 120
Tocchetti, C. G., Farmakis, D. T., Koop, Y., Andrés, M. S., Couch, L. S., Formisano, L., Ciardiello, F., Pane, F., Au, L., Emmerich, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3340 · Cited by 102
Self-citationSex-Specific Cardiovascular Risks of Cancer and Its Therapies
Wilcox, N. S., Rotz, S. J., Mullen, M., Song, E. J., Ky Hamilton, B., Moslehi, J., Armenian, S. H., Wu, J. C., Rhee, J.-W., & Ky, B. (2022) · Circulation Research · doi:10.1161/circresaha.121.319901 · Cited by 86
Self-citationPatterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Yang, F., Shay, C., Abousaud, M. I., Tang, C., Li, Y., Qin, Z. S., Saba, N. F., & Teng, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02568-y · Cited by 76
Zhang, Y., Sun, C., Li, Y., Qin, J., Amancherla, K. V., Jing, Y., Hu, Q., Liang, K., Zhang, Z., Ye, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo1981 · Cited by 71
Self-citationFrascaro, F., Bianchi, N., Sanguettoli, F., Marchini, F., Meossi, S., Zanarelli, L., Tonet, E., Serenelli, M., Guardigli, G., Campo, G. C., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247737 · Cited by 62
Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
Ammirati, E., Bizzi, E., Veronese, G., Groh, M., Heyning, C. M. V. D., Lehtonen, J. Y. A., de Chambrun, M. P., Cereda, A. F., Picchi, C., Trotta, L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.838564 · Cited by 61
Self-citationGao, F., Xu, T., Zang, F., Luo, Y., & Pan, D. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s469331 · Cited by 60
T cells in cardiac health and disease
Martín, P., & Sánchez‐Madrid, F. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185218 · Cited by 58
Immunopathogenesis and immunomodulatory therapy for myocarditis
He, W., Zhou, L. D., Xu, K., Li, H., Wang, J. J., Chen, C., & Wang, D. W. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2273-3 · Cited by 49
Cardiovascular toxicity of immune therapies for cancer
Palaskas, N. L., Ali, H.-J., Koutroumpakis, E., Ganatra, S., & Deswal, A. M. (2024) · BMJ · doi:10.1136/bmj-2023-075859 · Cited by 61
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Gergely, T. G., Drobni, Z. D., Kallikourdis, M., Zhu, H., Meijers, W. C., Neilan, T. G., Rassaf, T., Ferdinandy, P., & Varga, Z. V. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00986-9 · Cited by 57
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
Gergely, T. G., Drobni, Z. D., Sayour, N. V., Ferdinandy, P., & Varga, Z. V. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01068-8 · Cited by 54
Autoimmune Myocarditis, Old Dogs and New Tricks.
Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51
Self-citationPathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
Jiménez-Alejandre, R., Ruiz‐Fernández, I., & Martín, P. (2022) · Cancers · doi:10.3390/cancers14184494 · Cited by 50
Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions
Liu, C., Chen, H., Guo, S., Liu, Q., Chen, Z., Huang, H., Zhao, Q., Li, L., Cen, H., Jiang, Z., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115373 · Cited by 49
Buono, M. G. D., Bonaventura, A., Vecchié, A., Moroni, F., Golino, M., Bressi, E., Ponti, R. D., Dentali, F., Montone, R. A., Kron, J., et al. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14110 · Cited by 49
Lee, C., Drobni, Z. D., Zafar, A., Gongora, C. A., Zlotoff, D. A., Alvi, R. M., Taron, J., Rambarat, P. K., Schoenfeld, S. R., Mosarla, R. C., et al. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.008 · Cited by 49
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
Liu, N., Wang, X., Wang, Z., Yonemori, K., Fang, Y., Gao, J., Kong, X., & Wang, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01692-4 · Cited by 49
Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy
Nishi, M., Wang, P., & Hwang, P. M. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316697 · Cited by 46
Landscapes and mechanisms of CD8+ T cell exhaustion in gastrointestinal cancer
Ding, J., Yang, K., Zhou, H., Huang, Y.-F., Li, H., & Zong, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1149622 · Cited by 45
Thyroid disorders induced by immune checkpoint inhibitors
Karaviti, D., Kani, E.-R., Karaviti, E., Gerontiti, E., Michalopoulou, O., Stefanaki, K., Kazakou, P., Vasileiou, V., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-03718-2 · Cited by 40
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice
Mulholland, M., Kritikou, E., Katra, P., Nilsson, J., Björkbacka, H., Lichtman, A. H., Rodríguez, A., & Engelbertsen, D. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.005 · Cited by 39
Self-citationVascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318259 · Cited by 36
Self-citationImmune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
Liu, H.-T., Jiang, M., Deng, Z., Li, L., Huang, J.-L., Liu, Z., Li, L., & Zhong, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.737497 · Cited by 34
Liu, X., Wu, W., Fang, L., Liu, Y., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922782 · Cited by 33
Blood-brain barrier penetrating nanosystems enable synergistic therapy of glioblastoma
Sun, Y., Li, M., Zheng, M., Zou, Y., & Shi, B. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102310 · Cited by 31
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction
Chen, Y.-C., Dolladille, C., Rao, A., Palaskas, N. L., Deswal, A. M., Lehmann, L., Cautela, J., Courand, P., Hayek, S. S., Zhu, H., et al. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.01.020 · Cited by 30
Self-citationShen, L., Chen, H., & Wei, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.621858 · Cited by 28
Berner, F., & Flatz, L. (2023) · Immunological Reviews · doi:10.1111/imr.13258 · Cited by 28
Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission
Montisci, A., Palmieri, V., Liu, J. E., Vietri, M. T., Cirri, S., Donatelli, F., & Claudio Napoli, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.713694 · Cited by 27
Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis
Vasbinder, A. L., Ismail, A., Salem, J., & Hayek, S. S. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01915-5 · Cited by 26
Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports
Wang, C., Zhao, G., Zhang, Z., Yang, L., Liu, S., Li, G., Wang, H., Huang, J., Wang, S., & Li, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275254 · Cited by 26
Luo, Y., Tang, W., Zeng, Q., Duan, W., Li, S., Xiaosu, Y., & Bi, F. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.714460 · Cited by 24
Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review
Jensen, G. L., Wang, X., Kuempel, J., Palaskas, N. L., Chen, Z., Yu, W., Chen, Y., Mohammad, H., Luo, W., & Chang, J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00687.2024 · Cited by 24
Immune Cell Activation in Obesity and Cardiovascular Disease
Garcia, J. N., Wanjalla, C. N., Mashayekhi, M., & Hasty, A. H. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01222-4 · Cited by 25
Zou, D., Song, A., & Yong, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176574 · Cited by 22
Immune checkpoint inhibitor-associated cardiovascular toxicities: A review
Liu, G., Chen, T., Zhang, X., Hu, B., & Shi, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25747 · Cited by 24
Cardiac fibrosis in oncologic therapies
Packard, R. R. S. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100575 · Cited by 22
Wong, C., Lam, T.-H., Liao, S.-Y., Lau, Y., Tse, H., & So, B. Y. F. (2023) · Biomedicines · doi:10.3390/biomedicines11010107 · Cited by 21
Zhang, A., Yang, F., Gao, L., Shi, X., & Yang, J. (2022) · Cancer Management and Research · doi:10.2147/cmar.s374648 · Cited by 22
Liu, Z., Guo, L., Yan, Z., Li, L., Wu, X., Shi, J., He, J., Zhao, L., Liang, H., & Wang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.989275 · Cited by 20
Gilon, D., Iakobishvili, Z., & Leibowitz, D. W. (2022) · Vaccines · doi:10.3390/vaccines10020304 · Cited by 19
Zhang, X., Ge, N., Xiang, Z.-J., & Liu, T. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02760-2 · Cited by 20
Wang, S., Peng, D., Zhu, H. S., Min, W., Xue, M., Wu, R., Shao, Y., Pan, L., & Zhu, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1053370 · Cited by 19
Lou, B., Guo, M., Zheng, T., Liu, J., Wang, C., Chen, T., Chen, F., Fan, X., Gao, S., Xiao, L., et al. (2024) · Immunology · doi:10.1111/imm.13770 · Cited by 20
Krych, S., Jęczmyk, A., Jurkiewicz, M., Żurek, M., Jekiełek, M., Kowalczyk, P., Kramkowski, K., & Hrapkowicz, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158127 · Cited by 19
Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
Mao, X., Mao, C., Liu, J., Wang, X., & Mao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1584675 · Cited by 18
Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology
Chen, M., Xue, J., Wang, M., Yang, J., & Chen, T. (2023) · Cancers · doi:10.3390/cancers15113055 · Cited by 18
Cancer and Cardiovascular Disease: The Conjoined Twins
Zmaili, M. A., Alzubi, J. M., Alkhayyat, M. M., Albakri, A. A., Alkhalaileh, F., Longinow, J., & Moudgil, R. (2024) · Cancers · doi:10.3390/cancers16081450 · Cited by 18
Gao, C., Zeng, Y., Zhang, L., Wang, J., Yang, X., Li, K., Ren, H., & Liu, Z. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c01267 · Cited by 17
Fu, S., Guo, Z., Xu, X., Li, Y., Choi, S. Y. C., Zhao, P., Shen, W., Gao, F., Wang, C., Chen, S., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03590-5 · Cited by 17
Yajima, S., & Masuda, H. (2025) · Cancers · doi:10.3390/cancers17091594 · Cited by 16
Choudhary, A., Brinkley, D. M., Besharati, S., Meijers, W. C., Atkinson, J. B., Amancherla, K. V., Zhu, Q., Huang, S., Nguyen, L. S., Salem, J., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008563 · Cited by 16
Self-citationImmune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology
He, Y., Yu, H., Dai, S., He, M., Ma, L., Xu, Z., Luo, F., & Wang, L. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.01.024 · Cited by 17
Zhong, J., Sun, Z., Li, S., Liu, Y., Cao, Y., & Bao, J. (2023) · Discover Oncology · doi:10.1007/s12672-023-00718-y · Cited by 16
The inflammatory spectrum of cardiomyopathies
Musigk, N., Suwalski, P., Golpour, A., Fairweather, D., Klingel, K., Martı́n, P., Frustaci, A., Cooper, L. T., Lüscher, T. F., Landmesser, U., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1251780 · Cited by 17
Mitochondrial-derived peptides: New markers for cardiometabolic dysfunction
Rochette, L., Rigal, E., Dogon, G., Malka, G., Zeller, M., Vergely, C., & Cottin, Y. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.013 · Cited by 16
Overview of immune checkpoint inhibitor associated myocarditis mechanisms diagnostics and treatment
Feng, S., Zhao, B., Sha, S., Bu, X., Zhang, Z., Liu, G., & Chen, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677984 · Cited by 17
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer
Licata, L., Dieci, M. V., Angelis, C. D., Marchiò, C., Miglietta, F., Cortesi, L., Fabi, A., Schmid, P. E., Cortés, J., Pusztai, L., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102762 · Cited by 16
Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management
Nardin, S., Ruffilli, B., Costantini, P., Mollace, R., Taglialatela, I., Pagnesi, M., Chiarito, M., Soldato, D., Cao, D., Conte, B., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12070270 · Cited by 15
Zhang, Y., Feng, L., Zhu, Z., He, Y., & Li, X. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102735 · Cited by 14
Hu, Y., Liu, C., Jin, S., Yi, Z., Wang, C., Pan, X., & Huang, H. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02417-4 · Cited by 14
Dias, Y., Silva, V. A. O., de Carvalho, M. F., Herchenhorn, R., & Herchenhorn, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1712632 · Cited by 13
Miao, K., & Zhang, L. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.08.002 · Cited by 13
Li, Z., Xie, Y., Wang, T., Liu, Y., Tian, Y. E., & Hua, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631273 · Cited by 12
Zheng, X., Zhang, A., Xiao, Y., Guo, K., Sun, L., Ruan, S., & Fang, F. (2022) · Journal of Cancer · doi:10.7150/jca.78004 · Cited by 13
Turker, I., & Johnson, D. B. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2254218 · Cited by 12
Li, J., Chen, L., Liu, X., Zhang, M., & Liu, X. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.09.006 · Cited by 11
Immune Mechanisms of Viral, Autoimmune, and Immune Checkpoint Inhibitor‐Associated Myocarditis
Jo, W., Sun, V., & Čiháková, D. (2026) · Immunological Reviews · doi:10.1111/imr.70111 · Cited by 12
Kou, L., Wen, Q., Xie, X., Chen, X., Li, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1013186 · Cited by 12
Acute myocarditis: an overview of pathogenesis, diagnosis and management
Zafeiri, M., Knott, K. D., & Lampejo, T. (2024) · Panminerva Medica · doi:10.23736/s0031-0808.24.05042-0 · Cited by 12
DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway
Su, X., Liu, J., Tu, Z., Ji, Q., Li, J., & Liu, F. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1943 · Cited by 11
Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology
Adhikari, B. B., Shi, S., Dimond, E. P., Shelburne, N., Desvigne-Nickens, P. M., & Minasian, L. M. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.01.001 · Cited by 11
Expanding horizons of cancer immunotherapy: hopes and hurdles
Sonar, P. V., Singh, A. K., Mandadi, S., & Sharma, N. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1511560 · Cited by 11
Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy
Maetani, T., Hamaguchi, T., Nishimura, T., Marumo, S., & Fukui, M. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7644-21 · Cited by 10
Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering
Kojic, A., Moslehi, J. J., Ky, B., & Wu, J. C. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102261 · Cited by 10
Self-citationGlobal epidemiology of myocarditis: disparities in age, sex and geography
Klingel, K., Tschöpe, C., Yon, D. K., Mensah, G. A., Weber, B. N., Kontorovich, A., Lee, S., Cooper, L. T., & Ammirati, E. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01276-w · Cited by 9
Lin, Y., Yuan, X., & Chen, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.955527 · Cited by 9
Chen, Z., Lan, R., Tao, R., Li, T., Zhu, Y., Li, Y., Zhang, C., Mao, M., Gao, D., & Zuo, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-76829-5 · Cited by 8
Toublanc, A., Faure, M., Verdy, G., Rabeau, A., Houard, V., Veillon, R., Bardel, C., Vergnenègre, C., Santos, P. D. D., Mazières, J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114191 · Cited by 8
Izumi, R., Hashimoto, T., Kisanuki, H., Ikuta, K., Otsuru, W., Asakawa, S., Yamamoto, S., Misumi, K., Fujino, T., Shinohara, K., et al. (2024) · Cardio-Oncology · doi:10.1186/s40959-024-00288-0 · Cited by 8
Yang, X., Duan, X., Xia, Z., Huang, R., He, K., & Xiang, G. (2023) · Cardiovascular Therapeutics · doi:10.1155/2023/8774971 · Cited by 8
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Ostos-Mendoza, K. C., Saraiba-Rabanales, V., Gutierrez‐Gallegos, P., Wang, E., Koutroumpakis, E., Kumar, S., Khalaf, S. Z., Ali, H.-J., Deswal, A. M., & Palaskas, N. L. (2025) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.13 · Cited by 7
Zhang, Z., Yan, Z., Yuan, T., Zhao, X., Wang, M., Liu, G., Gan, L., & Qin, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549487 · Cited by 8
Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
Niimura, T., Goda, M., Miyata, K., Matsumoto, J., Yoshioka, T., Hamano, H., Aizawa, F., Yagi, K., Izawa‐Ishizawa, Y., Zamami, Y., et al. (2023) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1213771 · Cited by 7
Guan, Z., Yao, T., Liu, G., Liu, J., Guo, L., Li, Z., & Ma, J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1465743 · Cited by 7
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
Chen, Y., Jaffer, M., Zhou, L., Moslehi, J. J., Forsyth, P. A., & Fecher, L. A. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390594 · Cited by 7
Self-citationAdvances in research on molecular markers in immune checkpoint inhibitor‐associated myocarditis
Shao, J., Liu, C., & Wang, J. (2023) · Cancer Innovation · doi:10.1002/cai2.100 · Cited by 7
Metadata
- Authors
- Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N.
- Affiliations
- Vanderbilt University Medical Center (US)
- Brigham and Women's Hospital (US)
- Université Paris Cité (FR)
- Albert Einstein College of Medicine (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2021-03-01
- Volume
- 131
- Issue
- 5
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7919710
- OpenAlex
- W3134997217
- Cited by
- 237
- References
- 181
- Citations by year
- 2026: 60 · 2025: 46 · 2024: 46 · 2023: 32 · 2022: 40 · 2021: 13
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (PR191593)
- American Heart Association (18SRG34280018)
- Vanderbilt University
- Vanderbilt University Medical Center
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL131862, R01HL130861, R01HL141466, R01HL138475)
- National Institute of Allergy and Infectious Diseases (P01AI056299, P01AI039671)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, T cell-mediated inflammation, predictive biomarkers, diagnostic approach, cancer immunotherapy toxicity
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Myocarditis, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
